Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture

“We are delighted to make this strategic move into the oncology and molecular diagnostic spaces with the acquisition of EpiCapture,” stated John Gillard, President and Chief Executive Officer of Trinity Biotech. “This move supports our strategy of combining Trinity’s established capabilities with cutting edge technologies to address large scale, urgent and important clinical issues. In this case, our manufacturing expertise and New York State Department of Healthcertified Immco reference laboratory will enable us to advance the development and commercialization of EpiCapture’s epigenetic analysis technology, an innovative solution with the potential to significantly impact the clinical management of prostate cancer, providing a less invasive and more accurate method of monitoring disease progression.”
Share:
More News
Valerie Vanhooren, Co-Founder and CEO of Ona Therapeutics, added, “ADCs have transformed cancer treatment; however, the technology has been applied to a limited number of tumor targets. These limitations restrict the number of patients who can benefit from treatments and highlight the critical need to identify new broadly expressed tumor
“Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company’s commercially available iTANK platform, today announced that the Data Safety and Monitoring Board (DSMB) has completed its first
“Patients deserve more than the currently available treatment options. TAR-200 is a groundbreaking therapy for early-stage bladder cancer, designed to deliver a sustained local release of medication directly into the bladder—right where it is needed,” said Biljana Naumovic, U.S. President, Oncology, Solid Tumor, Johnson & Johnson Innovative Medicine. “This innovation
Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare, said, “Zurletrectinib has demonstrated outstanding efficacy and safety profile in adult, adolescent, and pediatric patients with tumors harboring NTRK fusion genes, bringing better treatment options for patients with solid tumors. The Company is expanding the scope of its solid tumor